Opioid Induced Constipation Treatment Market By Treatment Type (Prescription Medications, Over-the-Counter Medications, Injectable Medications), By Drug Class (Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs), Laxatives, Prokinetic Agents), By Application (Acute Opioid-Induced Constipation, Chronic Opioid-Induced Constipation, Preventive Treatment), By End-User (Hospitals, Outpatient Clinics, Home Care), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Opioid Induced Constipation Treatment Market was valued at USD 128.8 million in 2024-e and will surpass USD 201.6 million by 2030; growing at a CAGR of 7.7% during 2025 - 2030.

The opioid-induced constipation (OIC) treatment market addresses a significant challenge faced by individuals on opioid therapy. Opioids, while effective for pain management, can cause constipation as a common side effect, leading to discomfort and further health complications for patients. As opioid use continues to rise globally, particularly for chronic pain conditions, the prevalence of opioid-induced constipation also increases. This has driven the demand for effective treatments to manage and alleviate the symptoms of OIC, contributing to the growth of this market.

The OIC treatment market is characterized by a variety of treatment types, including prescription medications, over-the-counter (OTC) solutions, and injectable medications. Different drug classes, such as peripherally acting mu-opioid receptor antagonists (PAMORAs), laxatives, and prokinetic agents, are employed to relieve the symptoms of constipation. The market is further segmented by application, focusing on acute, chronic, and preventive treatments, while end-users primarily include hospitals, outpatient clinics, and home care settings. As awareness of OIC grows and new treatments are developed, the market for opioid-induced constipation treatment is expected to expand.

Prescription Medications Segment Dominates the Market Owing to Efficacy in Severe Cases

The prescription medications segment holds the largest share in the opioid-induced constipation treatment market. These medications are typically used to manage severe cases of OIC where over-the-counter solutions may not be effective. Prescription treatments include PAMORAs, such as methylnaltrexone and naloxegol, which target the opioid receptors in the gastrointestinal tract to alleviate constipation without affecting the pain-relieving effects of opioids.

Given the potency and targeted action of prescription medications, they are preferred in cases of chronic or severe OIC, particularly in patients receiving long-term opioid therapy for conditions like cancer or chronic pain disorders. As these medications offer significant relief from the discomfort of constipation while minimizing the risk of opioid withdrawal, their adoption is expected to continue to grow, ensuring the dominance of the prescription medications segment in the market.

Over-the-Counter Medications Segment Shows Rapid Growth Owing to Accessibility and Affordability

The over-the-counter (OTC) medications segment is witnessing rapid growth, driven by the increasing demand for easily accessible and affordable solutions to manage OIC. OTC medications, such as fiber supplements, stimulant laxatives, and osmotic agents, provide a convenient option for patients who experience mild to moderate OIC. These medications are often the first line of treatment for individuals who prefer non-prescription solutions or are experiencing temporary symptoms of constipation.

The OTC segment benefits from a growing awareness of OIC and the availability of self-administered treatments that do not require a doctor’s prescription. As healthcare professionals recommend the use of OTC treatments for mild cases, the demand for these medications is expected to rise, particularly in the outpatient and home care settings.

Peripherally Acting Mu-Opioid Receptor Antagonists (PAMORAs) Drug Class Leads the Market Owing to Targeted Action

The peripherally acting mu-opioid receptor antagonists (PAMORAs) drug class is the leading therapeutic class in the OIC treatment market, owing to its targeted action on opioid receptors in the gastrointestinal tract. Unlike traditional laxatives, which work by stimulating the entire digestive system, PAMORAs specifically block the opioid receptors in the intestines, improving bowel movement without interfering with the pain-relieving effects of opioids.

PAMORAs are particularly effective in managing chronic OIC, which is often seen in patients on long-term opioid therapy. The ability to manage constipation effectively without altering the opioid’s efficacy in pain relief has made PAMORAs the treatment of choice in severe cases of OIC, contributing to the growth of this drug class in the market.

Chronic Opioid-Induced Constipation Application Leads the Market Due to Long-Term Use of Opioids

The chronic opioid-induced constipation application dominates the market, driven by the long-term use of opioids in managing chronic pain conditions. Chronic pain disorders, such as cancer pain, neuropathy, and arthritis, require prolonged opioid use, which often results in persistent OIC. As such, the treatment of chronic OIC is a major focus within the market.

Given the need for long-term management, chronic OIC often requires a combination of pharmacological treatments, lifestyle modifications, and regular monitoring. The demand for effective, long-term solutions to chronic OIC has led to the dominance of this application, with prescription medications, particularly PAMORAs, playing a central role in managing the condition.

Preventive Treatment Segment Shows Steady Growth Owing to Increased Awareness and Early Intervention

The preventive treatment segment is showing steady growth, owing to the increased awareness of OIC and the benefits of early intervention. Preventive treatments, which include the use of laxatives and bowel-regulating agents at the onset of opioid therapy, are increasingly being recommended by healthcare providers to mitigate the risk of OIC.

By addressing constipation proactively, patients are able to avoid the more severe symptoms of OIC, reducing the need for more intensive treatments later on. The growing recognition of the importance of preventive care in opioid therapy, especially in patients starting long-term opioid use, is driving the growth of this segment.

Hospitals End-User Segment Holds the Largest Share Owing to High Volume of Patients on Opioid Therapy

The hospitals end-user segment holds the largest share in the opioid-induced constipation treatment market. Hospitals are the primary setting for patients who are undergoing major surgeries, receiving cancer treatments, or being treated for chronic pain conditions that necessitate the use of opioids. As these patients are at high risk of developing OIC, hospitals play a central role in the diagnosis and treatment of the condition.

Given the high volume of patients requiring opioid therapy, hospitals are the largest consumers of OIC treatments, particularly prescription medications and injectable treatments. The hospital environment also allows for more intensive monitoring and management of OIC, ensuring that patients receive appropriate treatment to relieve symptoms and prevent complications.

North America Leads the Market Owing to High Opioid Consumption and Regulatory Focus

North America is the largest market for opioid-induced constipation treatments, driven by the high levels of opioid consumption in the United States and Canada. The widespread use of opioids for pain management, particularly in chronic pain and cancer care, has led to a significant prevalence of OIC in the region.

Furthermore, the regulatory focus on opioid use in North America, particularly in response to the opioid crisis, has increased awareness of OIC and the need for effective treatments. As healthcare providers and patients become more proactive in managing OIC, the demand for specialized treatments in North America is expected to continue to grow.

Competitive Landscape and Key Players

The opioid-induced constipation treatment market is competitive, with several key players leading the way, including Ironwood Pharmaceuticals, Shire (now part of Takeda), Valeant Pharmaceuticals (now Bausch Health), and Mylan Pharmaceuticals. These companies are at the forefront of developing and marketing treatments for OIC, particularly PAMORAs and other prescription medications.

With the ongoing opioid epidemic and the increasing recognition of OIC as a significant side effect of opioid therapy, these companies are focused on developing innovative solutions to meet the growing demand for effective treatments. Research and development efforts are focused on creating new drug formulations, improving patient outcomes, and addressing the challenges of opioid dependency and abuse.

Recent Developments:

• In December 2024, Takeda Pharmaceuticals launched a new PAMORA-based treatment for opioid-induced constipation with improved patient compliance.
• In November 2024, Bristol-Myers Squibb received FDA approval for its new prokinetic agent designed for chronic OIC management.
• In October 2024, Valeant Pharmaceuticals announced the release of a next-generation laxative formula aimed at opioid-induced constipation in outpatient settings.
• In September 2024, Shire Pharmaceuticals, under Takeda, introduced a combination therapy targeting OIC with opioid pain relief.
• In August 2024, Ironwood Pharmaceuticals expanded its portfolio with an innovative oral treatment for opioid-induced constipation to improve digestive function.

List of Leading Companies:

• Shire Pharmaceuticals (Acquired by Takeda)
• Valeant Pharmaceuticals (Bausch Health)
• Progenics Pharmaceuticals (Acquired by Lantheus Medical Imaging)
• Bristol-Myers Squibb
• Pfizer Inc.
• Takeda Pharmaceuticals
• McNeil Consumer Healthcare (Johnson & Johnson)
• Ironwood Pharmaceuticals
• Allergan (Acquired by AbbVie)
• Mylan N.V.
• AbbVie Inc.
• AstraZeneca
• Novo Nordisk
• Salix Pharmaceuticals (A Division of Valeant)
• Mallinckrodt Pharmaceuticals

Report Scope: